Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(3):371–376. doi: 10.1038/bjc.1997.392

Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer.

M T Seymour 1, E C Moskovic 1, G Walsh 1, P Trott 1, I E Smith 1
PMCID: PMC2224053  PMID: 9252205

Abstract

The purpose of this study was to assess the usefulness of ultrasonography (US) in the assessment of the breast following primary medical therapy (PMT) of large operable breast cancer. A total of 52 patients were studied; all had invasive breast cancer, confirmed by core biopsy, with initial size > 4 cm by palpation, T2-3, N0-1, M0. PMT was with epirubicin, cisplatin and continuous infusional 5-fluorouracil, as previously described (Jones et al, 1994, J Clin Oncol 12: 1259-1265). Independent clinical and US assessments were made during PMT before surgery or biopsy. A total of 31 (60%) patients achieved complete clinical response (cCR), but in only five of these was the post-treatment ultrasound normal. Post-treatment sonographic findings of diffuse parenchymal distortion or a mass lesion without Doppler signal were associated with more favourable histology (pathological CR, non-invasive or microinvasive carcinoma), whereas a mass with Doppler positivity was more often associated with residual macroscopic invasive carcinoma. Patients who did not achieve cCR had a high incidence of residual macroscopic carcinoma (71%) regardless of the sonographic characteristics. With median follow-up of 27 months (range 12-43), ten (19%) patients have relapsed and six (12%) have died, but only one relapse has occurred within treated breast. Ultrasonography is a sensitive technique for assessing the response to PMT, particularly in patients who achieve cCR. It may be helpful in selecting those patients who do not require post-PMT surgery and in localizing abnormalities in those who do, particularly in those with cCR. However, clinicians should be aware that a residual US abnormality is by no means pathognomonic of residual cancer.

Full text

PDF
371

Images in this article

373Figure 1
on p.373

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abraham D. C., Jones R. C., Jones S. E., Cheek J. H., Peters G. N., Knox S. M., Grant M. D., Hampe D. W., Savino D. A., Harms S. E. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996 Jul 1;78(1):91–100. doi: 10.1002/(SICI)1097-0142(19960701)78:1<91::AID-CNCR14>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  2. Balu-Maestro C., Bruneton J. N., Geoffray A., Chauvel C., Rogopoulos A., Bittman O. Ultrasonographic posttreatment follow-up of breast cancer patients. J Ultrasound Med. 1991 Jan;10(1):1–7. doi: 10.7863/jum.1991.10.1.1. [DOI] [PubMed] [Google Scholar]
  3. Bonadonna G., Veronesi U., Brambilla C., Ferrari L., Luini A., Greco M., Bartoli C., Coopmans de Yoldi G., Zucali R., Rilke F. Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst. 1990 Oct 3;82(19):1539–1545. doi: 10.1093/jnci/82.19.1539. [DOI] [PubMed] [Google Scholar]
  4. Forouhi P., Walsh J. S., Anderson T. J., Chetty U. Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg. 1994 Feb;81(2):223–225. doi: 10.1002/bjs.1800810221. [DOI] [PubMed] [Google Scholar]
  5. Gawne-Cain M. L., Smith E., Darby M., Given-Wilson R. The use of ultrasound for monitoring breast tumour response to pro-adjuvant therapy. Clin Radiol. 1995 Oct;50(10):681–686. doi: 10.1016/s0009-9260(05)83312-4. [DOI] [PubMed] [Google Scholar]
  6. Jones A. L., Smith I. E., O'Brien M. E., Talbot D., Walsh G., Ramage F., Robertshaw H., Ashley S. Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol. 1994 Jun;12(6):1259–1265. doi: 10.1200/JCO.1994.12.6.1259. [DOI] [PubMed] [Google Scholar]
  7. Kedar R. P., Cosgrove D. O., Smith I. E., Mansi J. L., Bamber J. C. Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. Radiology. 1994 Mar;190(3):825–830. doi: 10.1148/radiology.190.3.8115634. [DOI] [PubMed] [Google Scholar]
  8. Moskovic E. C., Mansi J. L., King D. M., Murch C. R., Smith I. E. Mammography in the assessment of response to medical treatment of large primary breast cancer. Clin Radiol. 1993 May;47(5):339–344. doi: 10.1016/s0009-9260(05)81451-5. [DOI] [PubMed] [Google Scholar]
  9. Powles T. J., Hickish T. F., Makris A., Ashley S. E., O'Brien M. E., Tidy V. A., Casey S., Nash A. G., Sacks N., Cosgrove D. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol. 1995 Mar;13(3):547–552. doi: 10.1200/JCO.1995.13.3.547. [DOI] [PubMed] [Google Scholar]
  10. Smith I. E., Walsh G., Jones A., Prendiville J., Johnston S., Gusterson B., Ramage F., Robertshaw H., Sacks N., Ebbs S. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol. 1995 Feb;13(2):424–429. doi: 10.1200/JCO.1995.13.2.424. [DOI] [PubMed] [Google Scholar]
  11. Veronesi U., Bonadonna G., Zurrida S., Galimberti V., Greco M., Brambilla C., Luini A., Andreola S., Rilke F., Raselli R. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995 Nov;222(5):612–618. doi: 10.1097/00000658-199511000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Walsh J. S., Dixon J. M., Chetty U., Paterson D. Colour Doppler studies of axillary node metastases in breast carcinoma. Clin Radiol. 1994 Mar;49(3):189–191. doi: 10.1016/s0009-9260(05)81774-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES